Stefano Fiorucci

List of Publications by Year in Descending Order

224 papers	12,925 citations	58 h-index	105 g-index
254 ext. papers	14,510 ext. citations	6.2 avg, IF	6.38 L-index

#	Paper	IF	Citations
224	Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. *FASEB Journal*, **2022**, 36, e22060	0.9	3
223	Discovery of a Potent and Orally Active Dual GPBAR1/CysLTR Modulator for the Treatment of Metabolic Fatty Liver Disease.. *Frontiers in Pharmacology*, **2022**, 13, 858137	5.6	0
222	Immunomodulatory functions of FXR.. *Molecular and Cellular Endocrinology*, **2022**, 111650	4.4	3
221	Discovery of Bile Acid Derivatives as Potent ACE2 Activators by Virtual Screening and Essential Dynamics.. *Journal of Chemical Information and Modeling*, **2021**,	6.1	3
220	Linking liver metabolic and vascular disease via bile acid signaling. *Trends in Molecular Medicine*, **2021**,	11.5	3
219	Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1. *Journal of Medicinal Chemistry*, **2021**, 64, 16512-16529	8.3	1
218	The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy. *FASEB Journal*, **2021**, 35, e21271	0.9	6
217	Bile acids and their receptors in metabolic disorders. *Progress in Lipid Research*, **2021**, 82, 101094	14.3	32
216	The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. *Expert Opinion on Drug Discovery*, **2021**, 16, 1193-1208	6.2	3
215	Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential. *Frontiers in Oncology*, **2021**, 11, 663771	5.3	3
214	Bile Acids Activated Receptors in Inflammatory Bowel Disease. *Cells*, **2021**, 10,	7.9	4
213	Inverse Virtual Screening for the rapid re-evaluation of the presumed biological safe profile of natural products. The case of steviol from Stevia rebaudiana glycosides on farnesoid X receptor (FXR). *Bioorganic Chemistry*, **2021**, 111, 104897	5.1	1
212	Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction. *Biochemical Pharmacology*, **2021**, 188, 114564	6	3
211	Bile Acid Signaling in Inflammatory Bowel Diseases. *Digestive Diseases and Sciences*, **2021**, 66, 674-693	4	28
210	Bile acid metabolism and bile acid receptor signaling in metabolic diseases and therapy. *Liver Research*, **2021**, 5, 103-104	4.1	0
209	Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease. *Liver Research*, **2021**, 5, 119-141	4.1	4
208	Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders. *Current Opinion in Pharmacology*, **2020**, 53, 45-54	5.1	14

207	Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1. *Biochemical Pharmacology*, **2020**, 177, 113987	6	3
206	Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). *Expert Opinion on Investigational Drugs*, **2020**, 29, 623-632	5.9	21
205	The Bile Acid Receptor GPBAR1 Modulates CCL2/CCR2 Signaling at the Liver Sinusoidal/Macrophage Interface and Reverses Acetaminophen-Induced Liver Toxicity. *Journal of Immunology*, **2020**, 204, 2535-2551	5.3	12
204	GPBAR1 Activation by C6-Substituted Hyodeoxycholane Analogues Protect against Colitis. *ACS Medicinal Chemistry Letters*, **2020**, 11, 818-824	4.3	3
203	Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation. *Nutrients*, **2020**, 12,	6.7	5
202	Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2020**, 1865, 158733	5	12
201	Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain. *Frontiers in Chemistry*, **2020**, 8, 572885	5	32
200	Variability in Probiotic Formulations Revealed by Proteomics and Physico-chemistry Approach in Relation to the Gut Permeability. *Probiotics and Antimicrobial Proteins*, **2020**, 12, 1193-1202	5.5	5
199	Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties. *Nutrients*, **2019**, 11,	6.7	16
198	Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation. *Nutrients*, **2019**, 11,	6.7	12
197	Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders. *Handbook of Experimental Pharmacology*, **2019**, 256, 283-295	3.2	36
196	The Pharmacology of Bile Acids and Their Receptors. *Handbook of Experimental Pharmacology*, **2019**, 256, 3-18	3.2	41
195	Serum Bile Acid Levels Before and After Sleeve Gastrectomy and Their Correlation with Obesity-Related Comorbidities. *Obesity Surgery*, **2019**, 29, 2517-2526	3.7	11
194	Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties. *Molecules*, **2019**, 24,	4.8	3
193	Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1. *Scientific Reports*, **2019**, 9, 2504	4.9	11
192	The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic Dysfunctions. *Nutrients*, **2019**, 11,	6.7	19
191	Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2019**, 1864, 1422-1437	5	21
190	GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis. *Cellular and Molecular Gastroenterology and Hepatology*, **2019**, 8, 447-473	7.9	18

189	Chenodeoxycholic Acid: An Update on Its Therapeutic Applications. *Handbook of Experimental Pharmacology*, **2019**, 256, 265-282	3.2	19
188	Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists. *ACS Medicinal Chemistry Letters*, **2019**, 10, 504-510	4.3	15
187	Endocrine activities and adipogenic effects of bisphenol AF and its main metabolite. *Chemosphere*, **2019**, 215, 870-880	8.4	18
186	Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury. *ACS Medicinal Chemistry Letters*, **2019**, 10, 407-412	4.3	20
185	Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis. *FASEB Journal*, **2019**, 33, 2809-2822	0.9	26
184	Farnesoid X receptor modulators 2014-present: a patent review. *Expert Opinion on Therapeutic Patents*, **2018**, 28, 351-364	6.8	52
183	Disruption of TFG□SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand. *Pharmacological Research*, **2018**, 131, 17-31	10.2	19
182	Bile Acids Activated Receptors Regulate Innate Immunity. *Frontiers in Immunology*, **2018**, 9, 1853	8.4	164
181	Future trends in the treatment of non-alcoholic steatohepatitis. *Pharmacological Research*, **2018**, 134, 289-298	10.2	40
180	Amphiphilic polypeptides with prolonged enzymatic stability for the preparation of self-assembled nanobiomaterials.. *RSC Advances*, **2018**, 8, 34603-34613	3.7	11
179	Synthesis and characterization of well-defined poly(2-deoxy-2-methacrylamido-d-glucose) and its biopotential block copolymers via RAFT and ROP polymerization. *European Polymer Journal*, **2018**, 105, 26-37	5.2	9
178	Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators. *American Journal of Physiology - Heart and Circulatory Physiology*, **2017**, 312, H21-H32	5.2	25
177	Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis. *Scientific Reports*, **2017**, 7, 41055	4.9	10
176	BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. *Scientific Reports*, **2017**, 7, 42801	4.9	66
175	Hyodeoxycholic acid derivatives as liver X receptor □and G-protein-coupled bile acid receptor agonists. *Scientific Reports*, **2017**, 7, 43290	4.9	17
174	The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis. *Journal of Immunology*, **2017**, 199, 718-733	5.3	127
173	Gpbar1 agonism promotes a Pgc-1□dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice. *Scientific Reports*, **2017**, 7, 13689	4.9	25
172	Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases. *Inflammatory Bowel Diseases*, **2017**, 24, 123-135	4.5	9

171	Epoxide functionalization on cholane side chains in the identification of G-protein coupled bile acid receptor (GPBAR1) selective agonists. *RSC Advances*, **2017**, 7, 32877-32885	3.7	4
170	Nanotraps with biomimetic surface as decoys for chemokines. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2017**, 13, 2575-2585	6	9
169	Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases. *Frontiers in Pharmacology*, **2017**, 8, 162	5.6	22
168	Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity. *Frontiers in Pharmacology*, **2017**, 8, 505	5.6	42
167	New brominated flame retardants and their metabolites as activators of the pregnane X receptor. *Toxicology Letters*, **2016**, 259, 116-123	4.4	8
166	Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. *Scientific Reports*, **2016**, 6, 30802	4.9	35
165	Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands. *Scientific Reports*, **2016**, 6, 29320	4.9	11
164	Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity. *Steroids*, **2016**, 105, 59-67	2.8	14
163	The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. *Oncotarget*, **2016**, 7, 61021-61035	3.3	32
162	Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. *World Journal of Gastroenterology*, **2016**, 22, 2219-41	5.6	176
161	Phallusiasterol C, A New Disulfated Steroid from the Mediterranean Tunicate Phallusia fumigata. *Marine Drugs*, **2016**, 14,	6	5
160	Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists. *Scientific Reports*, **2016**, 6, 19008	4.9	33
159	Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension. *Pharmacological Research*, **2016**, 111, 749-756	10.2	11
158	Receptor-ligand interactions: Advanced biomedical applications. *Materials Science and Engineering C*, **2016**, 68, 890-903	8.3	20
157	Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa. *Journal of Gastroenterology*, **2015**, 50, 707-19	6.9	21
156	Farnesoid X receptor modulators (2011 - 2014): a patent review. *Expert Opinion on Therapeutic Patents*, **2015**, 25, 885-96	6.8	18
155	Interactions Between Nuclear Receptor SHP and FOXA1 Maintain Oscillatory Homocysteine Homeostasis in Mice. *Gastroenterology*, **2015**, 148, 1012-1023.e14	13.3	38
154	Cystathionine Ɣlyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids. *American Journal of Physiology - Heart and Circulatory Physiology*, **2015**, 309, H114-26	5.2	35

153	Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders. *Trends in Molecular Medicine*, **2015**, 21, 702-714	11.5	247
152	Diethylstilbestrol-scaffold-based pregnane X receptor modulators. *European Journal of Medicinal Chemistry*, **2015**, 103, 551-62	6.8	4
151	Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application. *Future Medicinal Chemistry*, **2015**, 7, 1109-35	4.1	27
150	Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism. *Scientific Reports*, **2015**, 5, 16605	4.9	21
149	The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma. *Scientific Reports*, **2015**, 5, 15403	4.9	5
148	Inhibition of chronic ulcerative colitis-associated adenocarcinoma development in mice by VSL#3. *Inflammatory Bowel Diseases*, **2015**, 21, 1027-37	4.5	45
147	Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling. *PLoS ONE*, **2015**, 10, e0129866	3.7	30
146	Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. *PLoS ONE*, **2015**, 10, e0141082	3.7	39
145	Bazedoxifene-scaffold-based mimetics of solomonsterols A and B as novel pregnane X receptor antagonists. *Journal of Medicinal Chemistry*, **2014**, 57, 4819-33	8.3	16
144	Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. *Journal of Medicinal Chemistry*, **2014**, 57, 8477-95	8.3	57
143	Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). *Journal of Medicinal Chemistry*, **2014**, 57, 7687-701	8.3	50
142	Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. *Journal of Medicinal Chemistry*, **2014**, 57, 937-54	8.3	57
141	Insights on pregnane-X-receptor modulation. Natural and semisynthetic steroids from Theonella marine sponges. *European Journal of Medicinal Chemistry*, **2014**, 73, 126-34	6.8	10
140	Incisterols, highly degraded marine sterols, are a new chemotype of PXR agonists. *Steroids*, **2014**, 83, 80-5	2.8	10
139	Marine and semi-synthetic hydroxysteroids as new scaffolds for pregnane X receptor modulation. *Marine Drugs*, **2014**, 12, 3091-115	6	12
138	Phallusiasterols A and B: two new sulfated sterols from the Mediterranean tunicate Phallusia fumigata and their effects as modulators of the PXR receptor. *Marine Drugs*, **2014**, 12, 2066-78	6	16
137	The HIV matrix protein p17 promotes the activation of human hepatic stellate cells through interactions with CXCR2 and Syndecan-2. *PLoS ONE*, **2014**, 9, e94798	3.7	5
136	Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. *PLoS ONE*, **2014**, 9, e106503	3.7	143

135	Targeting FXR in cholestasis: hype or hope. *Expert Opinion on Therapeutic Targets*, **2014**, 18, 1449-59	6.4	31
134	Dissociation of intestinal and hepatic activities of FXR and LXR supports metabolic effects of terminal ileum interposition in rodents. *Diabetes*, **2013**, 62, 3384-93	0.9	43
133	Isoswinholide B and swinholide K, potently cytotoxic dimeric macrolides from Theonella swinhoei. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 5332-8	3.4	15
132	Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. *Journal of Medicinal Chemistry*, **2013**, 56, 4701-17	8.3	41
131	CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. *Translational Oncology*, **2013**, 6, 784-93	4.9	39
130	FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. *Pharmacological Research*, **2013**, 77, 1-10	10.2	11
129	Epigenetic modulation by methionine deficiency attenuates the potential for gastric cancer cell dissemination. *Journal of Gastrointestinal Surgery*, **2013**, 17, 39-49; discussion p. 49	3.3	10
128	Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. *British Journal of Pharmacology*, **2013**, 168, 225-37	8.6	15
127	Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis. *Marine Drugs*, **2013**, 12, 36-53	6	17
126	Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. *Circulation*, **2013**, 127, 2114-24	16.7	93
125	Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. *PLoS ONE*, **2013**, 8, e63893	3.7	81
124	New tridecapeptides of the theonellapeptolide family from the Indonesian sponge Theonella swinhoei. *Beilstein Journal of Organic Chemistry*, **2013**, 9, 1643-51	2.5	8
123	Oxygenated polyketides from Plakinastrella mamillaris as a new chemotype of PXR agonists. *Marine Drugs*, **2013**, 11, 2314-27	6	38
122	The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. *PLoS ONE*, **2013**, 8, e54472	3.7	66
121	Quantitative NMR-derived interproton distances combined with quantum mechanical calculations of 13C chemical shifts in the stereochemical determination of conicasterol F, a nuclear receptor ligand from Theonella swinhoei. *Journal of Organic Chemistry*, **2012**, 77, 1489-96	4.2	73
120	Marine sponge steroids as nuclear receptor ligands. *Trends in Pharmacological Sciences*, **2012**, 33, 591-601	13.2	41
119	Modification in the side chain of solomonsterol A: discovery of cholestan disulfate as a potent pregnane-X-receptor agonist. *Organic and Biomolecular Chemistry*, **2012**, 10, 6350-62	3.9	15
118	Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide C. *Molecular BioSystems*, **2012**, 8, 1412-7		10

117	Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei. *Journal of Medicinal Chemistry*, **2012**, 55, 84-93	8.3	36
116	4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity. *Steroids*, **2012**, 77, 484-95	2.8	36
115	Chalinulasterol, a chlorinated steroid disulfate from the Caribbean sponge Chalinula molitba. Evaluation of its role as PXR receptor modulator. *Marine Drugs*, **2012**, 10, 1383-90	6	9
114	Farnesoid X receptor: from medicinal chemistry to clinical applications. *Future Medicinal Chemistry*, **2012**, 4, 877-91	4.1	37
113	Plakilactones from the marine sponge Plakinastrella mamillaris. Discovery of a new class of marine ligands of peroxisome proliferator-activated receptor *Journal of Medicinal Chemistry*, **2012**, 55, 8303-17	8.3	38
112	Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. *PLoS ONE*, **2012**, 7, e30443	3.7	47
111	Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. *FASEB Journal*, **2012**, 26, 3021-31	0.9	43
110	Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR- dependent manner. *Antiviral Therapy*, **2012**, 17, 669-78	1.6	14
109	The First Total Synthesis of Solomonsterol B, a Marine Pregnane X Receptor Agonist. *European Journal of Organic Chemistry*, **2012**, 2012, 5187-5194	3.2	15
108	Preliminary structure-activity relationship on theonellasterol, a new chemotype of FXR antagonist, from the marine sponge Theonella swinhoei. *Marine Drugs*, **2012**, 10, 2448-66	6	14
107	Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders. *Current Topics in Medicinal Chemistry*, **2012**, 12, 605-24	3	31
106	The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes. *PLoS ONE*, **2012**, 7, e35924	3.7	21
105	VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. *PLoS ONE*, **2012**, 7, e45425	3.7	76
104	Gene expression changes induced by HIPEC in a murine model of gastric cancer. *In Vivo*, **2012**, 26, 39-45	2.3	5
103	Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. *PLoS ONE*, **2011**, 6, e22978	3.7	67
102	Solomonsterols A and B from Theonella swinhoei. The first example of C-24 and C-23 sulfated sterols from a marine source endowed with a PXR agonistic activity. *Journal of Medicinal Chemistry*, **2011**, 54, 401-5	8.3	45
101	Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. *Journal of Medicinal Chemistry*, **2011**, 54, 1314-20	8.3	53
100	Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2011**, 1809, 157-65	6	50

99	Towards new ligands of nuclear receptors. Discovery of malaitasterol A, an unique bis-secosterol from marine sponge Theonella swinhoei. *Organic and Biomolecular Chemistry*, **2011**, 9, 4856-62	3.9	32
98	The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. *PLoS ONE*, **2011**, 6, e25637	3.7	221
97	Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. *British Journal of Pharmacology*, **2011**, 164, 1929-38	8.6	27
96	Inhibition of NF-B by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. *European Journal of Pharmacology*, **2011**, 668, 317-24	5.3	74
95	SHP-dependent and -independent induction of peroxisome proliferator-activated receptor- by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts. *Inflammation Research*, **2011**, 60, 577-87	7.2	34
94	Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. *Journal of Medicinal Chemistry*, **2011**, 54, 3065-75	8.3	55
93	Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. *Journal of Medicinal Chemistry*, **2011**, 54, 4590-9	8.3	47
92	The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. *PLoS ONE*, **2010**, 5, e13238	3.7	22
91	FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. *Journal of Lipid Research*, **2010**, 51, 771-84	6.3	296
90	The bile acid sensor FXR regulates insulin transcription and secretion. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2010**, 1802, 363-72	6.9	130
89	Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. *Progress in Lipid Research*, **2010**, 49, 171-85	14.3	108
88	Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. *Current Medicinal Chemistry*, **2010**, 17, 139-59	4.3	53
87	Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. *Molecular Pain*, **2010**, 6, 36	3.4	32
86	Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. *Biochemical Pharmacology*, **2010**, 80, 1700-7	6	69
85	FXR an emerging therapeutic target for the treatment of atherosclerosis. *Journal of Cellular and Molecular Medicine*, **2010**, 14, 79-92	5.6	57
84	The bile acid receptor FXR is a modulator of intestinal innate immunity. *Journal of Immunology*, **2009**, 183, 6251-61	5.3	370
83	The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. *Journal of Immunology*, **2009**, 183, 6657-66	5.3	98
82	Antiatherosclerotic effect of farnesoid X receptor. *American Journal of Physiology - Heart and Circulatory Physiology*, **2009**, 296, H272-81	5.2	143

81	The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. *Biochemical Pharmacology*, **2009**, 78, 1214-23	6	58
80	Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. *Trends in Pharmacological Sciences*, **2009**, 30, 570-80	13.2	248
79	A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. *Pharmacological Research*, **2009**, 59, 319-29	10.2	13
78	Farnesoid X receptor agonists in biliary tract disease. *Current Opinion in Gastroenterology*, **2009**, 25, 252-9	3	46
77	Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. *World Journal of Gastroenterology*, **2009**, 15, 2097-108	5.6	46
76	The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. *Hepatology*, **2008**, 47, 659-67	11.2	53
75	Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. *Anti-Cancer Drugs*, **2007**, 18, 1081-91	2.4	24
74	Targeting farnesoid X receptor for liver and metabolic disorders. *Trends in Molecular Medicine*, **2007**, 13, 298-309	11.5	151
73	A Hydrogen-Sulfide Releasing Derivative of Mesalamine Exhibits Markedly Enhanced Anti-Inflammatory Effects in Experimental Colitis. *FASEB Journal*, **2007**, 21, A131	0.9	
72	3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats. *Toxicology and Applied Pharmacology*, **2006**, 214, 199-208	4.6	6
71	Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. *FASEB Journal*, **2006**, 20, 765-7	0.9	42
70	Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 316, 325-35	4.7	214
69	Essential requirement for sphingosine kinase activity in eNOS-dependent NO release and vasorelaxation. *FASEB Journal*, **2006**, 20, 340-2	0.9	34
68	Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. *FASEB Journal*, **2006**, 20, 2118-20	0.9	676
67	The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. *Molecular Pharmacology*, **2006**, 70, 1164-73	4.3	127
66	Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. *Journal of Biological Chemistry*, **2006**, 281, 39105-13	5.4	61
65	Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives. *Journal of Medicinal Chemistry*, **2006**, 49, 4208-15	8.3	41
64	The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. *Gastroenterology*, **2006**, 131, 259-71	13.3	311

63	5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 319, 447-58	4.7	116
62	PPARs and other nuclear receptors in inflammation. *Current Opinion in Pharmacology*, **2006**, 6, 421-7	5.1	108
61	Unveiling hidden features of orphan nuclear receptors: the case of the small heterodimer partner (SHP). *Journal of Molecular Graphics and Modelling*, **2006**, 24, 362-72	2.8	25
60	A role for proteinase-activated receptor-1 in inflammatory bowel diseases. *Journal of Clinical Investigation*, **2006**, 116, 2056	15.9	4
59	Farnesoid X receptor: from structure to potential clinical applications. *Journal of Medicinal Chemistry*, **2005**, 48, 5383-403	8.3	108
58	Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 313, 604-12	4.7	178
57	Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 315, 58-68	4.7	147
56	Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. *Inflammatory Bowel Diseases*, **2005**, 11, 792-8	4.5	42
55	The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. *Hepatology*, **2005**, 42, 539-48	11.2	459
54	Dual COX-inhibitors: the answer is NO?. *Current Topics in Medicinal Chemistry*, **2005**, 5, 487-92	3	6
53	A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 314, 584-95	4.7	155
52	The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. *Molecular Pharmacology*, **2005**, 68, 551-8	4.3	68
51	Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 2349-54	9.4	29
50	Role of FXR in regulating bile acid homeostasis and relevance for human diseases. *Current Drug Targets Immune, Endocrine and Metabolic Disorders*, **2005**, 5, 289-303		75
49	Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. *Cardiovascular Drug Reviews*, **2004**, 22, 135-46		19
48	Enhanced anti-inflammatory potency of a nitric oxide-releasing derivative of flunisolide: role of nuclear factor-kappaB. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 310, 1096-102	4.7	18
47	Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 311, 1264-71	4.7	23
46	Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. *Circulation*, **2004**, 110, 1320-5	16.7	44

45	Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 309, 1174-82	4.7	40
44	Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, 721-6	9.4	51
43	Nitric oxide regulates immune cell bioenergetic: a mechanism to understand immunomodulatory functions of nitric oxide-releasing anti-inflammatory drugs. *Journal of Immunology*, **2004**, 173, 874-82	5.3	27
42	A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 15736-41	11.5	139
41	PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. *Hepatology*, **2004**, 39, 365-75	11.2	136
40	The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. *Gastroenterology*, **2004**, 127, 1497-512	13.3	353
39	Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. *Journal of the American College of Cardiology*, **2004**, 44, 635-41	15.1	39
38	Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. *Journal of Medicinal Chemistry*, **2004**, 47, 4559-69	8.3	144
37	A role for proteinase-activated receptor-1 in inflammatory bowel diseases. *Journal of Clinical Investigation*, **2004**, 114, 1444-56	15.9	65
36	Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma. *Anticancer Research*, **2004**, 24, 1255-60	2.3	18
35	Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 10937-41	11.5	109
34	Proteinase-activated receptors (PARs) and immune function. *Drug Development Research*, **2003**, 60, 65-70	3.1	3
33	Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. *FASEB Journal*, **2003**, 17, 1171-3	0.9	59
32	Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. *British Journal of Pharmacology*, **2003**, 139, 1351-9	8.6	45
31	NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. *Journal of Hepatology*, **2003**, 39, 932-9	13.4	68
30	Endothelial nitric oxide synthase: the Cinderella of inflammation?. *Trends in Pharmacological Sciences*, **2003**, 24, 91-5	13.2	150
29	A magic bullet for mucosal protection...and aspirin is the trigger!. *Trends in Pharmacological Sciences*, **2003**, 24, 323-6	13.2	48
28	Potential cardioprotective actions of no-releasing aspirin. *Nature Reviews Drug Discovery*, **2002**, 1, 375-82	64.1	115

27	Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. *Digestion*, **2002**, 66, 246-56	3.6	79
26	NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. *FASEB Journal*, **2002**, 16, 1645-7	0.9	39
25	NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 15770-5	11.5	70
24	NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. *Circulation*, **2002**, 106, 3120-5	16.7	44
23	6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. *Journal of Medicinal Chemistry*, **2002**, 45, 3569-72	8.3	574
22	Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. *Immunity*, **2002**, 17, 769-80	32.3	101
21	Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?. *Biochemical Pharmacology*, **2001**, 62, 1433-8	6	231
20	Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism. *Journal of Immunology*, **2001**, 166, 832-40	5.3	18
19	Nitric oxide-releasing NSAIDs: a review of their current status. *Drug Safety*, **2001**, 24, 801-11	5.1	58
18	Galectin-1 exerts immunomodulatory and protective effects on concanavalin A-induced hepatitis in mice. *Hepatology*, **2000**, 31, 399-406	11.2	133
17	NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund© adjuvant arthritis. *British Journal of Pharmacology*, **2000**, 130, 1399-405	8.6	69
16	21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. *British Journal of Pharmacology*, **2000**, 131, 1345-54	8.6	49
15	Anti-very late antigen-1 monoclonal antibody modulates the development of secondary lesion and T-cell response in experimental arthritis. *Laboratory Investigation*, **2000**, 80, 73-80	5.9	33
14	IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. *Journal of Immunology*, **2000**, 165, 5245-54	5.3	100
13	Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens. *Digestive Diseases and Sciences*, **1995**, 40, 2074-80	4	48
12	L-arginine/nitric oxide pathway modulates gastric motility and gallbladder emptying induced by erythromycin and liquid meal in humans. *Digestive Diseases and Sciences*, **1995**, 40, 1365-71	4	17
11	Involvement of CD44 variant isoforms in hyaluronate adhesion by human activated T cells. *European Journal of Immunology*, **1995**, 25, 2932-9	6.1	59
10	Abscess formation in hepatocellular carcinoma: complications of percutaneous ultrasound-guided ethanol injection. *Journal of Clinical Ultrasound*, **1993**, 21, 531-3	1	10

9	5-hydroxytryptamine 3-receptor antagonist modulates gallbladder emptying and motilin release induced by erythromycin. *Digestive Diseases and Sciences*, **1993**, 38, 2236-40	4	15
8	Effect of erythromycin on gallbladder emptying in diabetic patients with and without autonomic neuropathy and high levels of motilin. *Digestive Diseases and Sciences*, **1992**, 37, 1671-7	4	29
7	Erythromycin stimulates gallbladder emptying and motilin release by atropine-sensitive pathways. *Digestive Diseases and Sciences*, **1992**, 37, 1678-84	4	38
6	Placebo-controlled comparison of piroxicam-beta-cyclodextrin, piroxicam, and indomethacin on gastric potential difference and mucosal injury in humans. *Digestive Diseases and Sciences*, **1992**, 37, 1825-32	4	16
5	Control of gastric pH with ranitidine in critically ill patients. Comparison of two intravenous regimens. *Digestive Diseases and Sciences*, **1991**, 36, 583-7	4	12
4	Neurohumoral control of gallbladder motility in healthy subjects and diabetic patients with or without autonomic neuropathy. *Digestive Diseases and Sciences*, **1990**, 35, 1089-97	4	38
3	Duodenal osmolality drives gallbladder emptying in humans. *Digestive Diseases and Sciences*, **1990**, 35, 698-704	4	9
2	Type III procollagen peptide and PZ-peptidase serum levels in pre-cirrhotic liver diseases. *Clinica Chimica Acta*, **1985**, 148, 87-95	6.2	16
1	Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region		5